Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Nicola Potere
Observed names:
N. Potere,
Nicola POTERE,
Potere Nicola,
Potere, Nicola
Observed institutions:
University of Ottawa,
Università Campus Bio-Medico,
Virginia Commonwealth University,
Ottawa Hospital,
University of Chieti-Pescara,
Ospedale SS. Annunziata,
Ottawa Hospital Research Institute,
Virginia Commonwealth University Medical Center
show all 8
ORCID:
0000-0002-6585-4870
Observed ORCID:
0000-0002-6585-4870
OpenAlex ID:
A5065879650
Targeting the NLRP3 inflammasome in cardiovascular diseases
2021
·
Stefano Toldo
, Eleonora Mezzaroma
, et al.
·
Pharmacology & Therapeutics
·
328
Acute complications and mortality in hospitalized patients with coronavirus disease 2019: a systematic review and meta-analysis
2020
·
Nicola Potere
, Emanuele Valeriani
, et al.
·
Critical Care
·
193
PDF
The NLRP3 Inflammasome Inhibitor, OLT1177 (Dapansutrile), Reduces Infarct Size and Preserves Contractile Function After Ischemia Reperfusion Injury in the Mouse
2019
·
Stefano Toldo
, Adolfo Gabriele Mauro
, et al.
·
Journal of Cardiovascular Pharmacology
·
155
Canakinumab in a subgroup of patients with COVID-19
2020
·
Claudio Ucciferri
, Antonio Auricchio
, et al.
·
The Lancet Rheumatology
·
131
PDF
The role of IL-6 and IL-6 blockade in COVID-19
2021
·
Nicola Potere
, Alberto Batticciotto
, et al.
·
Expert Review of Clinical Immunology
·
123
Interleukin-1 and the NLRP3 inflammasome in COVID-19: Pathogenetic and therapeutic implications
2022
·
Nicola Potere
, Marco Giuseppe Del Buono
, et al.
·
EBioMedicine
·
111
The Role of NLRP3 Inflammasome in Pericarditis
2021
·
Adolfo G. Mauro
, Aldo Bonaventura
, et al.
·
JACC Basic to Translational Science
·
107
PDF
Low Density Lipoprotein Receptor-Related Protein-1 in Cardiac Inflammation and Infarct Healing
2019
·
Nicola Potere
, Marco Giuseppe Del Buono
, et al.
·
Frontiers in Cardiovascular Medicine
·
79
PDF
Novel Therapeutics and Upcoming Clinical Trials Targeting Inflammation in Cardiovascular Diseases
2024
·
Nicola Potere
, Aldo Bonaventura
, et al.
·
Arteriosclerosis Thrombosis and Vascular Biology
·
78
PDF
Inflammasome Signaling, Thromboinflammation, and Venous Thromboembolism
2023
·
Nicola Potere
, Antonio Abbate
, et al.
·
JACC Basic to Translational Science
·
69
Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case–control study
2020
·
Nicola Potere
, Marcello Di Nisio
, et al.
·
Annals of the Rheumatic Diseases
·
67
NLRP3 inflammasome and interleukin-1 contributions to COVID-19-associated coagulopathy and immunothrombosis
2023
·
Nicola Potere
, Evan Garrad
, et al.
·
Cardiovascular Research
·
55
PDF
Alirocumab in Acute Myocardial Infarction: Results From the Virginia Commonwealth University Alirocumab Response Trial (VCU-AlirocRT)
2019
·
Cory R. Trankle
, George Wohlford
, et al.
·
Journal of Cardiovascular Pharmacology
·
47
Unsaturated Fatty Acids to Improve Cardiorespiratory Fitness in Patients With Obesity and HFpEF
2019
·
Salvatore Carbone
, Hayley E. Billingsley
, et al.
·
JACC Basic to Translational Science
·
42
Developing LRP1 Agonists into a Therapeutic Strategy in Acute Myocardial Infarction
2019
·
Nicola Potere
, Marco Giuseppe Del Buono
, et al.
·
International Journal of Molecular Sciences
·
36
PDF
Low-dose subcutaneous tocilizumab to prevent disease progression in patients with moderate COVID-19 pneumonia and hyperinflammation
2020
·
Nicola Potere
, Marcello Di Nisio
, et al.
·
International Journal of Infectious Diseases
·
32
Interleukin-6 receptor blockade with subcutaneous tocilizumab improves coagulation activity in patients with COVID-19
2020
·
Marcello Di Nisio
, Nicola Potere
, et al.
·
European Journal of Internal Medicine
·
28
PDF
An Orally Available NLRP3 Inflammasome Inhibitor Prevents Western Diet–Induced Cardiac Dysfunction in Mice
2018
·
Salvatore Carbone
, Adolfo G. Mauro
, et al.
·
Journal of Cardiovascular Pharmacology
·
27
Frailty phenotype as a predictor of bleeding and mortality in ambulatory patients receiving direct oral anticoagulants
2022
·
Matteo Candeloro
, Marcello Di Nisio
, et al.
·
Journal of the American Geriatrics Society
·
22
Prevalence and Severity of Nonalcoholic Fatty Liver Disease Among Caregivers of Patients With Nonalcoholic Fatty Liver Disease Cirrhosis
2018
·
Mohammad Shadab Siddiqui
, Salvatore Carbone
, et al.
·
Clinical Gastroenterology and Hepatology
·
22
Direct oral anticoagulant plasma levels in hospitalized COVID-19 patients treated with dexamethasone
2021
·
Nicola Potere
, Matteo Candeloro
, et al.
·
Journal of Thrombosis and Thrombolysis
·
21
PDF
Colchicine in Coronary Artery Disease: Where Do We Stand?
2025
·
Aldo Bonaventura
, Nicola Potere
, et al.
·
Journal of Cardiovascular Pharmacology
·
16
Unmet needs and barriers in venous thromboembolism education and awareness among people living with cancer: a global survey
2024
·
Nicola Potere
, Isabelle Mahé
, et al.
·
Journal of Thrombosis and Haemostasis
·
16
PDF
IL-1 blockade in cardiovascular disease: an appraisal of the evidence across different inflammatory paradigms
2023
·
Aldo BONAVENTURA
, Francesco MORONI
, et al.
·
Minerva Cardiology and Angiology
·
16
Novel Pathophysiological, Diagnostic and Therapeutic Concepts in Acute and Recurrent Pericarditis
2023
·
Aldo Bonaventura
, Georgia K Thomas
, et al.
·
Reviews in Cardiovascular Medicine
·
16
PDF
Show more works
View as search
Works count:
77
Citation count:
2,017
H-index:
21
I10-index:
32
Year
Topic
Type
